Shillong Herald

Graft-versus-host disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Graft-versus-host disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

October 14
03:40 2021
Graft-versus-host disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
“Graft versus host disease (GVHD) Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Graft versus host disease (GVHD) market. A detailed picture of the Graft versus host disease (GVHD) pipeline landscape is provided, which includes the disease overview and Graft versus host disease (GVHD) treatment guidelines.

DelveInsight’s “Graft-versus-host disease Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Graft-versus-host disease pipeline landscapes. 

The report comprises Graft-versus-host disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Graft-versus-host disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Graft-versus-host disease pipeline products.     

Graft-versus-host disease Overview

Graft-versus-host disease (GvHD) is an immune condition that occurs when immune cells (T cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host’s tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant (stem Cell Transplantation).

Some of the key takeaways from the Graft-versus-host disease Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as CSL Behring, Medac, ElsaLys Biotech, Kadmon Therapeutics, Incyte Corporation, etc., are developing therapies for the treatment of Graft-versus-host disease.

  • Emerging therapies such as CSL 964 AAT (Zemaira), Obnitix, Leukotac (Inolimomab), KD025 (Belumosudil), Itacitinib, are expected to have a significant impact on the  Graft-versus-host disease market in the coming years.

Get an overview of pipeline landscape @ Graft-versus-host disease Clinical Trials Analysis 

Graft-versus-host disease Pipeline Therapies along with Key Players:

  • CSL 964 AAT (Zemaira): CSL Behring

  • Obnitix: Medac

  • Leukotac (Inolimomab): ElsaLys Biotech

  • KD025 (Belumosudil): Kadmon Therapeutics

  • Itacitinib: Incyte Corporation

Scope of Graft-versus-host disease Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: CSL Behring, Medac, ElsaLys Biotech, Kadmon Therapeutics, Incyte Corporation, and others.

  • Pipeline Therapies: CSL 964 AAT (Zemaira), Obnitix, Leukotac (Inolimomab), KD025 (Belumosudil), Itacitinib, and others.

Table of Contents

1

Graft-versus-host disease Report Introduction

2

Graft-versus-host disease Executive Summary

3

Graft-versus-host disease Overview

4

Graft-versus-host disease- Analytical Perspective In-depth Commercial Assessment

5

Graft-versus-host disease Pipeline Therapeutics

6

Graft-versus-host disease Late Stage Products (Phase II/III)

7

Graft-versus-host disease Mid Stage Products (Phase II)

8

Graft-versus-host disease Early Stage Products (Phase I)

9

Graft-versus-host disease Preclinical Stage Products

10

Graft-versus-host disease Therapeutics Assessment

11

Graft-versus-host disease Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Graft-versus-host disease Key Companies

14

Graft-versus-host disease Key Products

15

Graft-versus-host disease Unmet Needs

16 

Graft-versus-host disease Market Drivers and Barriers

17

Graft-versus-host disease Future Perspectives and Conclusion

18

Graft-versus-host disease Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Graft-versus-host disease Drugs Pipeline Report

Related Reports:

Graft-versus-host disease Market

DelveInsight’s ‘Graft-versus-host disease-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom)

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles